PMI Impact Malaria




PMI Impact Malaria in Rwanda

PMI Impact Malaria (IM) is the flagship global service delivery project of the U.S. President’s Malaria Initiative (PMI). To fight malaria and save lives, IM is supporting Rwanda’s national malaria control program (NMCP) in its efforts to strengthen malaria service delivery.

In 2019, IM began working with Rwanda’s NMCP to improve malaria case management at the community and public facility levels, with an emphasis on protecting those who are most at risk—particularly young children and pregnant women. 

To advance malaria service delivery in Rwanda, IM focuses mainly on improving the quality of and access to malaria case management. 


  • Rwanda Malaria Summary PMI Webpage
  • Malaria Service Delivery Photos PMI Impact Malaria Photo Library

Malaria Country Context 

Rwanda’s entire population of about 12.2 million people is at risk for malaria, including 1.8 million children less than five years of age. Malaria transmission is mesoendemic in the plains and prone to epidemics in the high plateaus and hills. In endemic zones, Malaria transmission occurs year-round with two peaks from May to June and from November to December following distinct rainy seasons. The malaria parasite species Plasmodium falciparum causes the majority of infections. 

The country made remarkable progress in the fight against malaria from 2005 to 2012, experiencing an 86% reduction in malaria incidence. However, between 2012 and 2016 the number of reported malaria cases increased 8-fold. Malaria continues to be a major public health problem in Rwanda, with an estimated 6.2 million cases and 3,300 deaths in 2018.  


This is PMI Impact Malaria’s geographic coverage in Rwanda:

PMI Impact Malaria has supported Rwanda’s NMCP in achieving these key accomplishments: 

  • Developed and digitized supportive supervision tools for malaria case management and malaria in pregnancy using approved Outreach, Training and Supportive Supervision Plus (OTSS+) checklists. 

  • Supported the development of a therapeutic efficacy study (TES) protocol to be implemented later in 2020. A TES assesses the efficacy of an antimalarial drug.  

  • Improved the quality of and access to malaria case management and prevention of malaria in pregnancy by hosting workshops to identify gaps in the country’s fight against malaria, share action plans to better control new data, and set priorities for following years. 


Click here for a printable version of this page: English and French

Photo Credit: Brant Stewart/PMI, Rwanda

Sources: PMI’s Rwanda Country BriefPMI’s Rwanda Malaria Operational Plan FY 2020, 2019 World Malaria Report Rwanda Country Profile, PMI Impact Malaria Rwanda, and Rwanda NMCP